InMed-logo-01

Management

Eric A Adams_InMed web photo

Eric A. Adams, MIBS

Chief Executive Officer & President

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in

capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well-respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies.

He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Learn More

Profile_Mike

Michael Woudenberg, P.Eng.

Chief Operating Officer

Mr. Woudenberg joined InMed with more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He brings valuable expertise in the development, technology transfer and commercialization of

active pharmaceutical ingredients (APIs) and drug products.

Prior to joining InMed in 2018, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC. His experience includes process and formulation development from lab/pre-clinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g. FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products.

Mr. Woudenberg received his Bachelor of Science, Chemistry and Bachelor of Engineering Science, Chemical at Western University of London, Ontario, Canada.
Learn More

Neeta Jagpal_INM web lowres

Netta Jagpal, CPA

Chief Financial Officer

Ms. Jagpal joins InMed with over 20 years of experience in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS) where she led a finance team through the initial public offering process.



Prior to D-Wave, Netta spent 11 years at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behaviour from Simon Fraser University.
Learn More

Profile_EricHsu_2

Eric C. Hsu, PhD

Senior Vice President, Pre-Clinical Research & Development

Dr. Hsu joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations.



Dr. Hsu's experience includes a wide array of activities, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines, and managing R&D budgets and timelines. Dr. Hsu is considered to be an expert in gene transfer and gene expression using vector systems.

Dr. Hsu received his Doctorate from the Department of Medical Biophysics at the University of Toronto and his Bachelor’s degree from McGill University.
Learn More

InMed_Colin Clancy_web

Colin Clancy

Vice President, Investor Relations & Corporate Communications

Colin Clancy is a seasoned corporate finance and investor relations executive with more than 18 years of experience across the pharmaceutical, legal cannabis, mining, and financial services sectors.



He has a proven track record of fostering strong capital markets engagement, driving strategic business development initiatives, and enhancing corporate visibility among global investors. Mr. Clancy currently serves as Vice President, Investor Relations & Corporate Communications at InMed Pharmaceuticals Inc. (NASDAQ: INM), where he leads the company’s investor relations strategy, capital markets communications, and supports a range of strategic corporate initiatives. Prior to joining InMed, he was Vice President of Investor Relations at Harvest One Cannabis Inc., a consumer packaged goods–focused cannabis company listed on the TSX Venture Exchange. Before Harvest One, Mr. Clancy held a business development role at Deloitte, where he played a key part in establishing the firm’s Canadian Cannabis practice between 2014 and 2017 during the advent of the legal cannabis system.

Mr. Clancy holds a Finance Degree from the Dublin Institute of Technology.
Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*